文献速递药物不良反应与药物警戒

脱靶5-羟色胺能药物活性意义:基于系统生物信息学方法的5-羟色胺综合征报告分析

Implications of Off-Target Serotoninergic Drug Activity: An Analysis of Serotonin Syndrome Reports Using a Systematic Bioinformatics Approach.
PubMed 文献 · Pharmacotherapy · 2018-07-29

本研究利用生物信息学与多药理学方法构建5-羟色胺能扩展生物活性矩阵(SEBM),分析71种5-羟色胺能药物在13种5-HT受体亚型及SERT的相互作用,并结合FAERS中按Hunter和Sternbach标准提取的SS报告计算PRR。结果显示三重受体相互作用药物SS报告比例显著升高,而5-HT激动剂比例显著降低,且两种诊断标准下参与度高的药物差异较大。

要点

  • 三重受体相互作用药物SS报告比例显著升高(Hunter标准PRR 1.72,95%CI 1.05-2.39)。
  • 5-HT激动剂SS报告比例显著降低(Hunter标准PRR 0.49,95%CI 0.17-0.81)。
  • 不同诊断标准下SS参与度高的药物存在较大差异。

核心结论

  • SEBM模型提示多药理学因素可能在SS中起作用,脱靶受体活性或可解释毒性严重程度与临床表现差异。

研究设计与样本

  • 利用TargetSearch程序表征71种5-羟色胺能药物在13种5-HT受体亚型及SERT的相互作用,并纳入NET、MAO和毒蕈碱受体的脱靶作用定义7个多药理学药物队列。
  • 从FAERS中按Sternbach和Hunter标准提取每种5-羟色胺能药物的SS报告,计算PRR并按药物生物活性队列汇总。

主要发现

  • 三重受体相互作用队列按Hunter标准平均PRR为1.72(95%CI 1.05-2.39),按Sternbach标准平均PRR为1.54(95%CI 1.29-1.79)。
  • 5-HT激动剂按Hunter和Sternbach标准平均PRR分别为0.49(95%CI 0.17-0.81)和0.49(95%CI 0.15-0.83)。
  • 两种诊断标准下SS参与度不成比例升高的药物差异较大。

局限性

  • 结论需进一步研究验证,脱靶受体活性与SS毒性严重程度及临床表现的关系尚待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Serotonergic adverse drug events (ADEs) are caused by enhanced intrasynaptic concentrations of 5-hydroxytryptamine (5-HT). No systematic process currently exists for evaluating cumulative 5-HT and off-target toxicity of serotonergic drugs. The primary study aim was to create a Serotonergic Expanded Bioactivity Matrix (SEBM) by using a molecular bioinformatics, polypharmacologic approach for assessment of the participation of individual 5-HT drugs in serotonin syndrome (SS) reports. DATA SOURCES: Publicly available databases including the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), ChEMBL, DrugBank, PubChem, and Kyoto Encyclopedia of Genes and Genomes (KEGG) were queried for computational and pharmacologic data. DESIGN: An in-house bioinformatics TargetSearch program ( http://dxulab.org/software) was used to characterize 71 serotonergic drugs interacting at 13 serotonin receptor subtypes and serotonin reuptake transporter protein (SERT). In addition, off-target interactions at norepinephrine transporter (NET), monoamine oxidase (MAO), and muscarinic receptors were included to define seven polypharmacological drug cohorts. Serotonin syndrome reports for each serotonergic drug were extracted from FAERS by using the Sternbach and Hunter criteria. MEASUREMENTS AND MAIN RESULTS: A proportional reporting adverse drug reaction (ADR) ratio (PRR) was calculated from each drug's total ADEs and SS case reports and aggregated by drug bioactivity cohorts. Triple-receptor interactions had a disproportionately higher number of SS cases using both the Hunter criteria (mean PRR 1.72, 95% CI 1.05-2.39) and Sternbach (mean PRR 1.54, 95% CI 1.29-1.79). 5-Hydroxytryptamine agonists were associated with a significantly lower proportion of SS cases using the Hunter and Sternbach criteria, respectively (mean PRR 0.49, 95% CI 0.17-0.81 and mean PRR 0.49, 95% CI 0.15-0.83). Drugs with disproportionately higher participation in SS vary considerably between the two diagnostic criteria. CONCLUSION: The SEBM model suggests a possible polypharmacological role in SS. Although further research is needed, off-target receptor activity may help explain differences in severity of toxicity and clinical presentation.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Culbertson VL, Rahman SE, Bosen GC, et al. Implications of Off-Target Serotoninergic Drug Activity: An Analysis of Serotonin Syndrome Reports Using a Systematic Bioinformatics Approach. Pharmacotherapy. 2018. PMID: 29972695. doi:10.1002/phar.2163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。